Angina

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study

Retrieved on: 
Monday, April 8, 2024
Observational study, Cardiovascular disease, University Medical Center, Patient, Angina, Șaeș, CCS, American College, University Medical Center Utrecht, DRS, Royal Brompton Hospital, MACE, Pharmaceutical industry

These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.

Key Points: 
  • These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.
  • Results were presented earlier today at the 73rd Annual Scientific Sessions of the American College of Cardiology in Atlanta, GA.
    REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
  • “Results from the REDUCER-I study continue to demonstrate the safety and effectiveness of Shockwave Coronary Sinus Reducer as a novel therapy for refractory angina,” said Dr. Verheye.
  • Results from COSIRA-II are intended to support the regulatory filing for US FDA approval of Shockwave Reducer.

Innovating "Treadmill Exercise Test AI-Assisted Interpretation System," CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Retrieved on: 
Tuesday, April 2, 2024
Depression, Thrombosis, Myocardial infarction, Sudden death, Cardiovascular disease, Exercise, Survival, Coronary artery disease, ECG, Hyperlipidemia, Patient, Palpitations, Angina, Cancer, AI, Death, Moyamoya disease, Chronic pain, Plaque, Diet, Receiver, Smoking, Cardiac catheterization, Stenosis, Oxygen, Heart, Atherosclerosis, Rupture, Ministry, Duke, Vascular occlusion, CAD

To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.

Key Points: 
  • To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.
  • The program also utilizes ten measured features and two derived features including maximal work output and peak heart rate to determine the severity of coronary artery stenosis.
  • Generally, coronary heart disease in patients of middle or senior age is presented as angina or myocardial infarction and is one of the primary causes of sudden death."
  • Dr. Wu stated, "Coronary artery stenosis is a multi-factorial condition related to smoking, advanced age, diabetes hypertension and hyperlipidemia.

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches

Retrieved on: 
Wednesday, March 20, 2024
Palpitations, Varenicline, Chest pain, Xerostomia, Dizziness, Weakness, Caregiver, Nervous, Indigestion, Sleep, Risk, Headache, NPN, Health, Nicotine, Angina, Internet, Stroke, Constipation, Smoke, Death, Heartburn, Health Canada, Arrhythmia, Nausea, Medicine, Nursing, Safety, Fatigue, Vomiting, Blurred vision, Allergy, Parent, Chronic pain, Advertising, Tobacco

Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

Key Points: 
  • Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.
  • Use authorized nicotine pouches only as directed:
    To date, Health Canada has authorized only one nicotine pouch , containing 4 mg of nicotine per dose.
  • Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.
  • There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024
Urinary tract infection, Patient, Medical Subject Headings, Marketing, Agency, Jaw, INN, Interferon beta-1a, Immune system, Fever, Tears, ATC, Disability, Multiple sclerosis, Kidney, Hypertension, International, Blood, RRMS, Attack, Spinal cord, Disease, Headache, Language, Brain, Myocardial infarction, Eye, Heart, Inflammation, Thyroid, Stroke, Head, Angina, European Medicines Agency, Infection, Coagulopathy, Lymphocyte, HIV, Select, Central nervous system, Human, Safety, Anatomy, Checklist, Sclerosis, IIA, Optic nerve, Neck, Rash, CD52, Medical device

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Fungal infection, Medical Subject Headings, Marketing, European Commission, Liver, INN, Nitrate, Woman, Allergy, PDE5, Pelvic floor dysfunction, ATC, Hypotension, Itraconazole, International, Man, European, Headache, Ageing, Language, Blood, CGMP, Mouth, Eye, Pulmonary hypertension, Erectile dysfunction, Stroke, Kidney, Kidney disease, Angina, Ketoconazole, HIV, Ritonavir, Tablet, Indinavir, Select, Committee, Patient, Penis, Liver disease, Risk management, Anatomy, Medicine, Dialysis, IIA, Diabetes, CHMP, Medical device

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Moyamoya disease, Disease, NYHA, Language, Heart, Death, Angina, Coronary artery disease, Tablet, Select, Human, Patient, Facial muscles, Anatomy, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, Agency, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Disease, NYHA, Language, Heart, Death, Angina, European Medicines Agency, Coronary artery disease, Tablet, Select, Human, Patient, Anatomy, Medicine, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 10, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, Agency, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Disease, NYHA, Ivabradine, Language, Heart, Death, Angina, European Medicines Agency, Coronary artery disease, Tablet, Select, Human, Patient, Facial muscles, Anatomy, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 10, Status: Authorised

Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina

Retrieved on: 
Sunday, November 12, 2023
Safety, Incidence, Ischemia, Patient, Dobutamine, Glucose, MRCP, Ex-gay movement, Angina, Quality of life, Moyamoya disease, Professor, Facial muscles, Medical imaging, Pharmaceutical industry

BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing innovative therapies designed to improve patient symptoms and function by enhancing cellular energetics, today announced positive topline results from the randomized, double-blind, placebo-controlled Phase 2 IMPROVE-ISCHEMIA trial, evaluating ninerafaxstat, a novel cardiac mitotrope and partial fatty acid oxidation (pFOX) inhibitor, in patients with chronic stable angina.

Key Points: 
  • Treatment with ninerafaxstat was well tolerated and no safety signals were observed.
  • At 8-weeks, treatment with ninerafaxstat demonstrated clinically and statistically significant improvements in dobutamine stress-induced ischemic left ventricular (LV) wall motion abnormalities.
  • This robust anti-ischemic effect was not dependent on changes in myocardial blood flow, consistent with a direct, metabolic mechanism of action of ninerafaxstat targeting the cardiomyocyte.
  • “The randomized, placebo-controlled IMPROVE-ISCHEMIA trial provides detailed insights into the anti-ischemic effects of ninerafaxstat in symptomatic patients with stable angina," said Juhani Knuuti, M.D., Ph.D., Professor and Director of Turku PET Centre in Turku, Finland and chief investigator of the IMPROVE-ISCHEMIA trial.

New Treatment Restores Sense of Smell in Patients with Long COVID

Retrieved on: 
Monday, November 20, 2023
Jefferson Health, Health, RSNA, Neck, Research, Head, Food, Nose, Patient, Arrhythmia, Headache, Heart rate, Appetite, Stroke, COVID-19, Smell, Phantosmia, Newsroom, Infection, Angina, Autonomic nervous system, Digestion, Ear, Education, Quality of life, Society, Environment, Radiology, Radiation, COVID, Blood pressure, Medical imaging, Pharmaceutical industry, Dentistry, Birth control, Parosmia

Parosmia, a condition where the sense of smell no longer works correctly, is a known symptom of COVID-19.

Key Points: 
  • Parosmia, a condition where the sense of smell no longer works correctly, is a known symptom of COVID-19.
  • While most patients do recover their sense of smell over time, some patients with long COVID continue to have these symptoms for months, or even years, after infection, negatively impacting their appetite for food and their overall quality of life.
  • The distorted sense of smell can also affect smell perception, and some patients may suffer from phantosmia, a condition that causes people to detect smells—foul or pleasant—that aren't in their environment.
  • To assess a possible treatment for patients with long-term post-COVID parosmia, researchers looked at the potential benefits of CT-guided stellate ganglion block.